pyrogallic-acid-restores-doxycycline-susceptibility-in-multidrug-resistant-enterotoxigenic-escherichia-coli
Pyrogallic Acid Restores Doxycycline Susceptibility in Multidrug-Resistant Enterotoxigenic Escherichia Coli

Pyrogallic Acid Restores Doxycycline Susceptibility in Multidrug-Resistant Enterotoxigenic Escherichia Coli

A research investigation published in One Health Advances demonstrates that pyrogallic acid, a plant-derived polyphenolic compound isolated from the stem of Cotinus species, restores the therapeutic susceptibility of multidrug-resistant enterotoxigenic Escherichia coli to doxycycline. Fecal contamination of food supplies and drinking water sources facilitates widespread transmission, causing significant losses in livestock productivity and placing substantial strain on international public health systems. Compounding this challenge, the extensive diversity of circulating ETEC serotypes has historically limited the cross-protective efficacy of existing vaccines, forcing clinical medicine and animal husbandry to rely heavily on chemical antimicrobial agents for prevention and metaphylactic disease control. Decades of sustained selective pressure have accelerated the emergence of multidrug-resistant isolates, rendering conventional antimicrobial therapies ineffective and prompting an urgent search for natural adjuvant compounds capable of reversing established resistance phenotypes.

To uncover prospective botanical scaffolds that could serve as standalone antimicrobials or resistance-modifying adjuvants, the investigators screened an experimental library containing twenty-five distinct polyphenolic compounds derived from traditional medicinal plants. Antimicrobial evaluations conducted against representative reference strains, including E. coli ATCC 25922 alongside porcine ETEC clinical isolates designated K88, K99, and 987P, identified pyrogallic acid as a particularly potent candidate. Quantitative susceptibility assays established that pyrogallic acid exhibited a minimum inhibitory concentration of 256 micrograms per milliliter and a minimum bactericidal concentration of 512 micrograms per milliliter, demonstrating strong intrinsic antibacterial efficacy. Initial susceptibility profiling confirmed that the tested ETEC strains possessed pronounced baseline resistance to multiple therapeutic antibiotic classes, specifically sulfafurazole, clindamycin, and doxycycline. Subsequent checkerboard broth microdilution experiments revealed that pairing pyrogallic acid with these existing antibiotics markedly enhanced overall antibacterial activity, yielding fractional inhibitory concentration index values spanning from 0.1875 to 0.50, thereby meeting the formal pharmacological threshold for synergistic interaction across all evaluated multidrug-resistant strains.

Quantitative shifts in minimum inhibitory concentrations highlighted the pronounced adjuvant potency of the botanical compound across distinct drug classes. In the presence of pyrogallic acid, the minimum inhibitory concentration of sulfafurazole dropped precipitously from a baseline range of 1024 to 2048 micrograms per milliliter down to 16 to 512 micrograms per milliliter, while the minimum inhibitory concentration of clindamycin plunged from 4096 micrograms per milliliter to 32 micrograms per milliliter. When evaluated in combination with doxycycline against the highly virulent ETEC K88 strain selected for detailed downstream characterization, the minimum inhibitory concentration of doxycycline decreased from baseline values of 2 to 64 micrograms per milliliter down to 0.25 to 16 micrograms per milliliter, with the combined regimen achieving inhibition at 32 micrograms per milliliter of pyrogallic acid and 16 micrograms per milliliter of doxycycline. Time-kill kinetic assays recorded over ten-hour incubation intervals showed concentration-dependent bactericidal action, culminating in complete bacterial sterilization within four hours at the minimum bactericidal concentration. Furthermore, whereas doxycycline monotherapy at 16 or 64 micrograms per milliliter exhibited negligible killing alone, co-administration with sub-inhibitory pyrogallic acid induced rapid, visible bacterial lysis and clarified the suspension during exponential growth phases.

Parallel toxicological and safety assessments demonstrated that pyrogallic acid maintains a highly favorable biocompatibility profile at pharmacologically active concentrations. When exposed to freshly isolated sheep erythrocytes across concentrations ranging from 0 to 512 micrograms per milliliter for one hour, the compound induced less than five percent hemolytic activity relative to a fully lysed Triton X-100 reference control. Similarly, cytotoxicity evaluations performed on intestinal porcine enterocyte J2 cell monolayers using lactate dehydrogenase release assays revealed that exposure to 512 micrograms per milliliter of pyrogallic acid for thirty minutes resulted in less than fifteen percent enzyme release. In addition to preserving mammalian cell membrane integrity, crystal violet microplate staining demonstrated that sub-inhibitory concentrations of pyrogallic acid, notably 128 micrograms per milliliter, significantly attenuated the biomass of established ETEC K88 biofilms after forty-eight hours of cultivation. This selective suppression of the extracellular protective matrix occurred without impairing planktonic bacterial growth rates, an important pharmacological attribute that reduces the selective survival pressures that typically accelerate the evolutionary development of de novo antimicrobial resistance.

High-resolution ultrastructural examinations employing scanning electron microscopy and transmission electron microscopy revealed profound morphological and structural breakdowns in ETEC K88 cells exposed to 256 micrograms per milliliter of pyrogallic acid for four hours. Untreated control bacteria consistently displayed classic short rod-shaped morphologies, sharply demarcated outer envelopes, intact and continuous cell walls, and homogenous cytoplasmic densities. Conversely, scanning electron micrographs of treated specimens documented extensive envelope corrugation, irregular cellular surface contours, pronounced membrane invaginations, and widespread cellular lysis. Transmission electron micrographs corroborated these destructive alterations, capturing widespread physical discontinuities within the peptidoglycan cell wall layer, localized envelope bulging, distorted cell contours, and loose, uneven internal cytoplasmic densities.

In vitro infection models using intestinal porcine enterocyte J2 monolayers demonstrated that pyrogallic acid significantly curtails the virulence and invasive capabilities of ETEC K88 in a concentration-dependent manner. Treatment with a sub-inhibitory concentration of 64 micrograms per milliliter reduced bacterial adherence by 34.5 percent and suppressed cell invasion by 52.7 percent compared to untreated infected controls, with inhibition escalating to two-fold and eight-fold reductions in adhesion and invasion, respectively, at 256 micrograms per milliliter. When cell monolayers were infected with ETEC K88 at a multiplicity of infection of 100 to 1, co-administration of 32 micrograms per milliliter pyrogallic acid alongside 128 micrograms per milliliter doxycycline achieved complete elimination of persistent intracellular bacteria, whereas doxycycline monotherapy failed to clear the intracellular niche. Furthermore, dual-fluorescence viability staining utilizing calcein-acetoxymethyl ester and propidium iodide confirmed remarkable cytoprotection. Unchecked ETEC infection produced 85.7 percent host epithelial cell mortality characterized by membrane blebbing and cytoplasmic condensation, whereas post-infection treatment with pyrogallic acid at 128 and 256 micrograms per milliliter rescued cell survival, reducing mortality to 46.0 percent and restoring baseline viability to 96.2 percent.

Biochemical assays designed to delineate the molecular mechanisms underlying bacterial envelope disruption confirmed that pyrogallic acid alters both outer and inner membrane permeability in a concentration-dependent manner. Fluorometric measurements utilizing the non-polar probe 1-N-phenylnaphthylamine revealed immediate, concentration-dependent increases in outer membrane fluorescence following compound administration, signifying extensive permeabilization of the lipopolysaccharide leaflet. Concurrently, bioluminescent quantification of extracellular and intracellular adenosine triphosphate levels demonstrated a progressive depletion of intracellular adenosine triphosphate pools after twenty minutes of exposure, a physiological hallmark reflecting inner cytoplasmic membrane destabilization and metabolic uncoupling. These complementary findings confirm that the adjuvant compromises the dual-barrier architecture characteristic of Gram-negative bacterial envelopes, simultaneously permitting external fluorescent probes to enter hydrophobic spaces and inducing the pathological leakage of essential intracellular nucleotides and energy reserves required for cellular survival.

Competitive envelope-binding assays and computational docking simulations clarified the precise structural targets engaged by pyrogallic acid within the bacterial cell envelope. While the exogenous supplementation of outer membrane phosphatidylethanolamine exerted only a marginal impact on pyrogallic acid susceptibility, the addition of exogenous peptidoglycan produced a concentration-dependent neutralization of antibacterial activity, wherein an exogenous concentration of 128 micrograms per milliliter raised the minimum inhibitory concentration by sixteen-fold. In silico molecular docking performed through AutoDock Vina corroborated this interaction, identifying a favorable binding affinity of negative 1.283 kilocalories per mole between pyrogallic acid and peptidoglycan. Three-dimensional structural modeling resolved two conventional hydrogen bonds spanning bond lengths between 2.95 and 3.00 angstroms between the small molecule and the peptidoglycan backbone.

Beyond physical envelope destabilization, transcriptomic profiling and quantitative reverse transcription polymerase chain reaction assays revealed that pyrogallic acid exerts powerful regulatory effects on bacterial transcription. Exposure to 256 micrograms per milliliter of the compound for four hours significantly down-regulated key virulence determinants in ETEC K88, causing significant reductions in mRNA transcript levels encoding the type 1 fimbrial adhesin fimH, the F4 fimbrial structural subunit faeG, the hemolysin hlyA, and the enterotoxin genes eltA and estA, relative to 16S ribosomal RNA reference controls. Crucially, graded exposure to 0 to 32 micrograms per milliliter of pyrogallic acid produced dose-dependent transcriptional repression of tet(A), the primary structural gene encoding the active-efflux transmembrane pump responsible for extruding tetracycline-class antibiotics. By concurrently suppressing fimbrial adhesin and toxin expression while repressing the tet(A) efflux pump, pyrogallic acid neutralizes bacterial pathogenicity while preventing the active extrusion of doxycycline, promoting intracellular antibiotic retention and sustained ribosomal targeting within resistant bacteria.

Mice inoculated intraperitoneally with 50 million colony-forming units exhibited progressive body weight loss and acute systemic infection when left untreated, whereas animals receiving a combined dual regimen comprising 40 milligrams per kilogram pyrogallic acid and 7.5 milligrams per kilogram doxycycline exhibited robust body weight recovery comparable to full-dose doxycycline monotherapy at 15 milligrams per kilogram, despite utilizing half-doses of each agent. Quantitative peritoneal lavage plating at six hours post-infection established that the dual combination regimen achieved superior bacterial clearance compared to either monotherapy, while serum profiling revealed significant reductions in circulating proinflammatory cytokines interleukin-1 beta and interleukin-18. Furthermore, histopathological examination of ileal tissue sections demonstrated that combination therapy counteracted ETEC-induced mucosal pathology, significantly increasing goblet cell numbers, elongating intestinal villus length, and reducing crypt depth. These findings demonstrate that pyrogallic acid restores doxycycline efficacy in vivo while supporting mucosal barrier repair, presenting a promising adjuvant approach to combating multidrug-resistant bacterial infections.

Subject of Research: Pyrogallic acid as an antibiotic adjuvant against multidrug-resistant enterotoxigenic Escherichia coli

Article Title: Pyrogallic acid restores doxycycline susceptibility against multidrug-resistant enterotoxigenic Escherichia coli

Article References: Gao, T., Zhu, J., Li, S., Chen, J., Wu, Q., Yang, K., Liu, W., Li, C., Chen, M., Wang, Y., Tan, M., Yuan, F., Guo, R., & Zhou, D. (2026). Pyrogallic acid restores doxycycline susceptibility against multidrug-resistant enterotoxigenic Escherichia coli. One Health Advances, 4(1), Article 42. https://doi.org/10.1186/s44280-026-00149-8

Image Credits: AI Generated

DOI: 10.1186/s44280-026-00149-8

Keywords: pyrogallic acid, doxycycline, enterotoxigenic Escherichia coli, antibiotic adjuvant, multidrug resistance, tet(A) efflux pump, peptidoglycan, bacterial biofilm, IPEC-J2 cells, electron microscopy, membrane permeability, antimicrobial synergy, murine infection model, proinflammatory cytokines, intestinal barrier repair, Cotinus